OTLK Outlook Therapeutics

Outlook Therapeutics to Participate in Cantor Fitzgerald’s Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021

Outlook Therapeutics to Participate in Cantor Fitzgerald’s Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021

MONMOUTH JUNCTION, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate in the Cantor Fitzgerald “Eyeing Key Events and Programs in the Ophthalmology Space in 2021” virtual panel being held on Friday, February 19, 2021 from 10:30 AM – 12:00 PM ET.

The panel, hosted by Kristen Kluska, Equity Research Analyst at Cantor Fitzgerald, will discuss market opportunities across numerous indications in the ophthalmology space and will include highlights from participating company pipelines, previously reported datasets, and upcoming 2021 milestones and events.

To attend the virtual panel, please register in advance .

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit .

CONTACTS:

Media Inquiries:

Harriet Ullman

Assistant Vice President

LaVoieHealthScience

T: 617-669-3082

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247 



EN
17/02/2021

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Formal Dispute Resolution Request for O...

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS...

April 7, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Ea...

March 25, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant are being sold together at a combined public offering price of $0.2...

March 24, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics Announces Proposed Public Offering ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to th...

March 23, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note ...

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the “Existing Note”) and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC (the “New Note”). Under the amendment to the Existing Note, the maturity date of the Ex...

March 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch